- $160.20m
- $0.49m
- 11
- 32
- 58
- 26
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.94 | ||
| Price to Tang. Book | 0.94 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -80.87% | ||
| Return on Equity | -61.69% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 17.9 | 9.73 | 24.99 | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Its pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Its pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
Directors
- Chen Schor PRE (48)
- Nick Harvey CFO (60)
- Carrie Krehlik CHO (53)
- Francesco Galimi SVP (53)
- Don Healey CTO (59)
- Jeffrey Chodakewitz IND (65)
- Steve Dubin IND (67)
- Carl Gordon IND (56)
- Aya Jakobovits IND (68)
- Michael Kauffman IND (57)
- Bastiano Sanna IND (46)
- Andrew Sinclair IND (49)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 5th, 2016
- Public Since
- January 26th, 2018
- No. of Shareholders
- 16
- No. of Employees
- 143
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 82,153,984
- Address
- 200 BERKELEY STREET, 19TH FLOOR, BOSTON, 02116
- Web
- https://www.adicetbio.com/
- Phone
- +1 6174822333
- Auditors
- KPMG LLP
Upcoming Events for ACET
Adicet Bio Inc Annual Shareholders Meeting
Adicet Bio Inc Annual Shareholders Meeting
Q2 2024 Adicet Bio Inc Earnings Release
Similar to ACET
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Adicet Bio share price?
As of Today at 19:00 UTC, shares in Adicet Bio are trading at $1.95. This share price information is delayed by 15 minutes.
How has the Adicet Bio share price performed this year?
Shares in Adicet Bio last closed at $1.95 and the price had moved by -67.77% over the past 365 days. In terms of relative price strength the Adicet Bio share price has underperformed the S&P500 Index by -73.18% over the past year.
What are the analyst and broker recommendations for Adicet Bio?
The overall consensus recommendation for Adicet Bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Adicet Bio dividend yield?
Adicet Bio does not currently pay a dividend.
Does Adicet Bio pay a dividend?
Adicet Bio does not currently pay a dividend.
When does Adicet Bio next pay dividends?
Adicet Bio does not currently pay a dividend.
How do I buy Adicet Bio shares?
To buy shares in Adicet Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Adicet Bio?
As of the previous close price of $1.95, shares in Adicet Bio had a market capitalisation of $160.20m.
Where are Adicet Bio shares listed?
Here are the trading details for Adicet Bio:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ACET
What kind of share is Adicet Bio?
Based on an overall assessment of its quality, value and momentum Adicet Bio is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Adicet Bio share price forecast for 2024?
The analyst consensus target price for shares in Adicet Bio is $9.00. That is 361.54% above the last closing price of $1.95.
Analysts covering Adicet Bio currently have a consensus Earnings Per Share (EPS) forecast of -$1.86 for the next financial year.
What is the trend in the Adicet Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adicet Bio. Over the past six months, its share price has outperformed the S&P500 Index by +10.37%.
As of the last closing price of $1.95, shares in Adicet Bio were trading -4.86% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Adicet Bio PE Ratio?
The Adicet Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Adicet Bio?
Adicet Bio's management team is headed by:
- Chen Schor - PRE
- Nick Harvey - CFO
- Carrie Krehlik - CHO
- Francesco Galimi - SVP
- Don Healey - CTO
- Jeffrey Chodakewitz - IND
- Steve Dubin - IND
- Carl Gordon - IND
- Aya Jakobovits - IND
- Michael Kauffman - IND
- Bastiano Sanna - IND
- Andrew Sinclair - IND